Biogen, Eisai releases four-year data on aducanumab; EMA stamps Eidos' aTTR therapy with orphan designation
→ After an attempt to resurrect faith in their Alzheimer’s drug BAN2401, using a small subset of patients from a closely watched Phase II trial on Thursday, Biogen $BIIB and Eisai followed up on Friday with long term data from a Phase I extension study of its other experimental Alzheimer’s drug, aducanumab. The Phase Ib trial now has four years of results, and an analysis of data suggests aducanumab played a role in a continued slowing of clinical decline in patients over 36 months and 48 months, Biogen said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.